# US 2009/0221827 A1 · Processes for the preparation of different forms of (s)-(+)-clopidogrel besylate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221827 A1
- Document ID: US20090221827A1
- Status: Published application
- Kind: A1
- Application number: 12/065,386
- Filed: 2006-08-28
- Published: 2009-09-03
- Earliest claimed: 2005-09-05
- Assignees: Cadila Healthcare Limited
- Inventors: Braj Bhushan Lohray; Vidya Bhushan Lohray; Bipin Pandey; Mayank Ghanshyambhai Dave; Parind Narendra Dholakia
- Web page: https://patentgrep.com/patent/US20090221827A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are the improved processes for the preparation of different forms of (S)-(+)-Clopidogrel besylate, pharmaceutical compositions containing them and their use in medicine.

## Claims

### Claim 1

A process for the preparation of amorphous form of (S)-(+)-Clopidogrel besylate comprising,
i. treating Clopidogrel base with benzene sulfonic acid in suitable solvent(s) selected from tetrahydrofuran, methyl isobutyl ketone, or their suitable mixtures
ii. removing the solvent to obtain the amorphous form.

### Claim 2

A process for the preparation of crystalline form of (S)-(+)-Clopidogrel besylate comprising,
i. treating Clopidogrel base with benzene sulfonic acid in suitable solvent(s) selected from methyl tertiary butyl ether, suitable C2-C12 alcohols which may be linear or branched, primary, secondary or tertiary alcohols or their suitable mixtures
ii. suitably removing the solvent.

### Claim 3 (depends on 2)

A process for the preparation of crystalline form of (S)-(+)-Clopidogrel besylate as claimed in claim 2, wherein optionally, the reaction mixture is seeded with crystals of (S)-(+)-Clopidogrel besylate.

### Claim 4 (depends on 1)

A process for the preparation of crystalline form of (S)-(+)-Clopidogrel besylate wherein the amorphous (S)-(+)-Clopidogrel besylate as prepared in claim 1, is further converted to the crystalline form by dissolving in suitable solvent(s), selected from methyl tertiary butyl ether, suitable C2-C12 alcohols which may be linear or branched, primary, secondary or tertiary alcohols or their suitable mixtures and subsequently suitably removing the solvent.

### Claim 5 (depends on 4)

A process for the preparation of crystalline form of (S)-(+)-Clopidogrel besylate as claimed in claim 4 wherein optionally, the reaction mixture is further seeded with crystals of (S)-(+)-Clopidogrel besylate.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the besylate salts of Clopidogrel as claimed in claim 1 prepared according to the present invention.
